
Recent trials reveal LSD's potential to significantly reduce anxiety symptoms in GAD, offering a promising alternative to traditional treatments.
Dr Fava is associate dean for clinical and translational research at Harvard Medical School in Boston, Massachusetts. He is psychiatrist-in-chief in the Department of Psychiatry at Massachusetts General Hospital and vice chair of the Executive Committee on Research at the Massachusetts General Hospital in Boston. He is also executive director of the Clinical Trials Network & Institute, and the Slater Family Professor of Psychiatry at Harvard Medical School.
Recent trials reveal LSD's potential to significantly reduce anxiety symptoms in GAD, offering a promising alternative to traditional treatments.
The original STAR*D authors refute claims of a violated protocol.
Learn about REL-1017, the medication that has the potential to be the first single agent oral NMDAR antagonist for the adjunctive treatment of depression.